orforglipron semaglutide Eli Lilly's investigational oral GLP-1, orforglipron, delivered superior blood glucose reduction and weight loss across three pivotal phase 3 diabetes trials, including outperforming oral in the head-to-head study. The results further orforglipron

When used with insulin or sulphonylureas, consider reducing the dose of these medications to decrease the risk of hypoglycaemia

Treating Autoimmune Disease with Diet & Supplementation Dietary modifications represent one of the most powerful interventions for addressing autoimmune conditions, with food choices directly influencing inflammatory pathways, gut barrier function, microbiome composition, and immune activation states

Producers of dairy, sports nutrition and functional food products can capitalize on healthier lifestyle trends

Eligible workers in firms with some union workers have a higher average take up rate (80%) than eligible workers in firms with no union workers (74%) [Figure 3.7]

In SUSTAIN-6 (N=3,297, cardiovascular outcomes trial for semaglutide), cholelithiasis occurred in 1.5% of semaglutide patients versus 0.8% of placebo patients over 104 weeks [7]